GDPR Compliant | FDA 21 CFR Part 11 | ISO 27001 Certified

The End-to-End Benefit-Risk Decision Engine

Trusted by Pharmaceutical Leaders

When regulatory decisions can make or break a drug's future, you need more than data—you need complete benefit-risk visibility. From preclinical framing to post-approval surveillance, anticipate your drug's success from day 1.

The Benefit-Risk Evaluation Challenge

Pharmaceutical teams face mounting pressure to demonstrate drug safety and efficacy across every stage—from regulatory submission to market access and post-approval surveillance. Yet traditional evaluation methods create critical vulnerabilities.

FIRST STEP

Time-Consuming Manual Analysis

Traditional benefit-risk assessments can take up to 18 months per drug, delaying critical go/no-go decisions and market authorization filings.

SECOND STEP

Incomplete Evidence Synthesis

Fragmented data sources and manual literature reviews miss critical safety signals, leaving gaps in regulatory submissions and HTA dossiers.

THIRD STEP

High Failure Costs

With 9 out of 10 drugs failing (57% efficacy issues, 17% safety concerns) at an average cost of $2.3B per approval, incomplete benefit-risk intelligence compounds financial risk across your entire portfolio.

One Platform.
Complete Visibility.

From Clinical Framing to Automated Outputs—Five Integrated Stages for Comprehensive Benefit-Risk Intelligence.

Step 1
Define Your Strategic Foundation

Clinical Framing

Set protocol parameters (drug, dosage, comparator), establish key endpoints and decision criteria, and frame your regulatory strategy from day one—ensuring alignment across clinical, regulatory, and market access teams.

Set drug & comparator

Align to EMA/FDA/PMDA

Define data protocols

Step 2
AI-POWERED DATA INTELLIGENCE ENGINE

Building the world's largest benefit-risk intelligence database

Once your framework is defined, 24 proprietary AI models process millions of data points from clinical trials, RWE, and regulatory submissions—identifying thousands of risk signals across your portfolio. Our BRTM then validates these insights, isolating key risks and benefits for regulatory decisions.

24 AI models repository

Validated risk signals

Prioritized key insights

Regulatory-ready evidence

Step 3
Aggregate and Analyze at Unprecedented Scale

AI-Powered Data Processing

Our 24 clinician-trained AI models process your clinical trial data alongside the world's largest benefit-risk database (100+ billion data points from RWE, scientific literature, and regulatory submissions). What used to take 18 months now completes in seconds.

60% faster evaluation time

9x more insights detected

70% cost reduction vs. CROs

Step 4
Identify What Matters Most

Strategic Analysis

Pinpoint Key Benefits and Key Risks tailored to your submission strategy. Compare against competitors with precision, and build evidence-based arguments that align with regulatory expectations and HTA frameworks.

3x DDI detection boost

Evidence-based pricing

Patient stratification profiling

Step 5
Monitor Evolving Signals with Precision

Decision Intelligence

Focus on the endpoints that drive regulatory decisions. Track safety signals in real-time as new evidence emerges, and adapt your strategy based on post-marketing surveillance data—all within a transparent, auditable dashboard.

"For the first time in our history, we successfully achieved a benefit-risk drill-down prediction based on 9x more insights, anticipating thromboembolic risks and re-routing millions in development funds."

Global R&D Team

Sanofi

Step 6
Generate Submission-Ready Documents

Automated Outputs

Auto-generate study reports, regulatory dossiers, and HTA submissions with full audit trails for compliance. Share analyses across cross-functional teams and maintain version control throughout the lifecycle.

PSUR / PBRER (Periodic Safety Update Reports)

Risk Management Plans (RMP)

CTD 2.5 B-R sections

HEOR report generation

Built by scientists. 
Trusted by pharmaceutical leaders.

Founded in 2018 by pharmacoepidemiology experts, ArcaScience bridges cutting-edge AI with pharmaceutical regulatory science. Our platform supports benefit-risk decisions across the entire drug lifecycle—from clinical development through post-marketing surveillance.

ArcaScience won 100% of its deals when facing traditional consulting companies. By 2025, 80% of pharma will have adopted AI benefit-risk-enabled solutions.

IDC Top 10 
Predictions for Life Sciences

2024

Scientific Rigor

Developed by PhD-level experts in pharmacoepidemiology and clinical data science. Our methodologies are grounded in pharmacoepidemiology best practices and align with regulatory expectations.

Proven Track Record

Supporting 50+ regulatory submissions across 12 therapeutic areas, including dermatology, immunology, oncology, and rare diseases. Trusted by 20+ blue-chip pharmaceutical clients worldwide.

Regulatory Compliance

Designed to meet EMA, FDA, and PMDA standards. Fully compliant with FDA 21 CFR Part 11, GDPR, and ISO 27001 requirements for data integrity, audit trails, and electronic signatures.

Ready to see how it works for your pipeline?

Accelerate Decisions Across the Drug Lifecycle

From early-stage portfolio prioritization to post-marketing safety monitoring, ArcaScience adapts to your specific phase and therapeutic area. Explore how teams like yours leverage our platform at every critical milestone.

Phase 1

Phase 1 titre

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Discover it
Phase 2

Phase 2 titre

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Discover it
Phase 3

Phase 3 titre

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Discover it
Submission

Submission titre

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Discover it
Post-Marketing

Post-Marketing titre

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Discover it
Market Access

Market Access titre

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Discover it

Not sure which use case fits your needs?

Talk to an Expert

The Science Behind the Platform

Founded in 2018 by a team of pharmacoepidemiology experts, ArcaScience was built to solve a $13 billion market problem: the lack of comprehensive, real-time benefit-risk intelligence. Our mission is to revolutionize drug evaluation and become the world leader in benefit-risk assessment—replacing legacy service models with transparent, AI-powered decision intelligence.

100B+ Data Points

The world's most comprehensive benefit-risk database (AS Profiling Base 100b®), layering 100% of publicly available scientific literature, RWE, and regulatory submissions.

Peer-Reviewed Methodologies

Published research validating our AI ensemble models for phenotyping, safety signal detection, and comparative effectiveness analysis.

Collaborative Partnerships

Working alongside leading research institutions, regulatory bodies, and pharmaceutical innovators to continuously refine our platform with real-world feedback.

Compliance by design

Pharmaceutical data demands the highest standards. ArcaScience is architected from the ground up to meet global regulatory requirements, ensuring your benefit-risk analyses are audit-ready and legally defensible.

Ready to Transform Your Benefit-Risk Evaluations?

Join 20+ pharmaceutical leaders who've cut evaluation time by 60% and costs by 70%. See how ArcaScience delivers complete benefit-risk intelligence—from clinical framing to automated submissions.